The Ministry of Health logged more than 6,500 domestic COVID-19 cases in Vietnam on Wednesday, down over 1,300 from a day before.
Thirty-six provinces and cities registered 6,555 locally-infected patients, compared to 7,911 domestic cases in 38 provinces and cities on Tuesday, while another four infections were imported from abroad, the health ministry said.
A total of 1,184 cases were detected in the community whereas the remainder were found in isolated areas or centralized quarantine facilities.
Ho Chi Minh City reported 4,449 of the latest domestic infections, Binh Duong Province 631, Dong Nai Province 271, Dong Thap Province 244, Khanh Hoa Province 147, and Tay Ninh Province 120.
Since the fourth COVID-19 wave began in Vietnam on April 27, the country has registered 117,042 community transmissions in 62 out of its 63 provinces and cities.
Ho Chi Minh City is taking the lead with 77,189 patients, followed by Binh Duong Province with 9,540, Bac Giang Province with 5,735, Long An Province with 3,931, Dong Nai Province with 2,985, Dong Thap Province with 2,641, and Tien Giang Province with 1,855.
By comparison, Vietnam confirmed 106 community cases in the first wave from January 23 to April 16, 2020, 554 in the second from July 25 to December 1, 2020, and 910 in the third from January 28 to March 25, 2021.
The health ministry confirmed 4,511 recoveries on Wednesday, bringing the total to 27,457 recovered patients.
The death toll has risen to 630 after 106 fatalities were announced the same day, including 91 in Ho Chi Minh City.
The Southeast Asian nation has overall recorded 118,612 domestic and 2,207 imported cases since the COVID-19 pandemic first hit it on January 23, 2020.
Health workers gave 258,077 vaccine doses today.
Over five million jabs have been administered to medical workers, teachers, factory workers, and other frontline staff since Vietnam rolled out inoculation on March 8.
Nearly 451,000 people have been fully vaccinated.
The Vietnamese government expects to obtain 175 million shots of various vaccines, including 51 million Pfizer-BioNTech jabs, by early 2022.
It set a target of immunizing two-thirds of a population of nearly 98 million people against COVID-19 by the first quarter of next year.